Last modified: January 10, 2010
Offices[edit]
People[edit]
Web Presences[edit]
- Biotech & Life Sciences
- Pharmaceutical
Industries[edit]
Parent Company[edit]
Acquisitions / Subsidiaries[edit]
Paid Sources[edit]
Keywords[edit]
|
|
Description[edit]
Nabriva Therapeutics is one of the few companies in recent years innovative enough to embark upon developing a new class of antibiotics: pleuromutilins. These unique antimicrobial compounds interfere with bacterial protein synthesis VIA a specific interaction with the 23S rRNA of the 50S bacterial ribosome subunit. These compounds offer a distinct profile and show no cross-resistance with any other class of antibiotics. Nabriva’s world class medicinal chemistry expertise achieved, for the very first time, the development of parenterally & orally available pleuromutilins clearing the way for IV to oral step-down therapy. This achievement constitutes a very significant milestone in providing appropriate medication for the combat against life-threatening bacterial infections.
Nabriva’s two systemic products, BC-3205 and BC-3781, are being developed for both oral and IV administration with extensive phase I data becoming available during 2009. The Company also has a Phase I non-systemic pleuromutilin product candidate, BC-7013.
Innovation[edit]
Activities[edit]
| Jobs by SimplyHired |
- No jobs were found for this particular company. Please visit the job board to search for more.
| Nabriva Therapeutics Job Trends | Nabriva Therapeutics Jobs |
- Biotech Showcase 2010 - Presenting Companies (3 subscribers)
This Company is Being Watched in
Recent Updates |
|---|
| Nabriva Therapeutics has been added to the Ecosystem. |